Between Dec News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Synovial sarcoma and myxoid round cell liposarcoma are rare, chemo-refractory malignancies with a poor prognosis once metastasized. Current treatment regimens are limited, and a

1. Patients in the KarXT (xanomeline–trospium) group reported a significant reduction in Positive and Negative Syndrome Scale (PANSS) score compared to those in the placebo group. 2. Majority of adverse events were mild-to-moderate, with no treatment-related fatalities or increase in extrapyramidal motor symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: Current antipsychotic therapies for schizophrenia

December 8, 2023 2:03 pm Between Dec 6 and Dec 7 2023 an entity connected...

1. One-third of patients with a cancer signal were correctly diagnosed to have cancer. 2. Patients in the true-positive group underwent more procedures and surgeries compared to those in the false-positive group. Evidence Rating Level: 2 (Good) Study Rundown: Cancer is a leading cause of death worldwide with nearly two million new cases expected to be diagnosed

1. One-third of patients with a cancer signal were correctly diagnosed to have cancer. 2. Patients in the true-positive group underwent more procedures and surgeries compared to those in the false-positive group. Evidence Rating Level: 2 (Good) Study Rundown: Cancer is a leading cause of death worldwide with nearly two million new cases expected to